Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-α- difluoromethylornithine

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1922-1925

  Iten, Monika ^a   Mett, Helmut ^b   Evans, Amanda ^b   Enyaru, John C K ^c   Brun, Reto ^a   Kaminsky, Ronald ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b CIBA GEIGY LTD   (Switzerland)

^c Livestock Health Research Institute Uganda   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; ORNITHINE DECARBOXYLASE;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA GAMBIENSE; TRYPANOSOMIASIS;

EID: 0030824384     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1922     Document Type: Article

References (26)

1. Bacchi, C. J., J. Garofalo, D. Mockenhaupt, P. P. McCann, K. A. Diekema, A. E. Pegg, H. C. Nathan, E. A. Mullanfy, L. Chunosoff, A. Sjoerdsma, and S. H. Hutner. 1983. In vivo effects of DL-α-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. Mol. Biochem. Parasitol. 7:209-225.
2. Bacchi, C. J., J. Garofalo, A. Santana, J. C. Hannan, A. J. Bitonti, and P. P. McCann. 1989. Trypanosoma brucei brucei: regulation of ornithine decarboxylase in procyclic forms and trypomastigotes. Exp. Parasitol. 68:392-402.
3. Bacchi, C. J., H. C. Nathan, T. Livingston, G. Valladares, M. Saric, P. D. Sayer, A. R. Njogu, and A. B. Clarkson. 1990. Differential susceptibility to DL-α-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob. Agents Chemother. 34:1183-1188.
4. Bacchi, C. J., J. Garofalo, M. Ciminelli, D. Rattendi, B. Goldberg, P. P. McCann, and N. Yarlett. 1993. Resistance to DL-α-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense: role of S-adenosylmethionine. Biochem. Pharmacol. 46:471-481.
5. Bales, J. D., S. M. Harrison, D. L. Mbwabi, and P. J. Schechter. 1989. Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann. Trop. Med. Parasitol. 1:111-114.
6. Baltz, T., D. Blatz, Ch. Giroud, and J. Crockett. 1985. Cultivation in a semidefined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J. 4:1273-1277.
7. 6b. Bellofatto, V., A. A. Fairlamb, G. B. Henderson, and G. A. M. Cross. 1987. Biochemical changes associated with α-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Mol. Biochem. Parasitol. 25:227-238.
8. Bitonti, A. J., C. J. Bacchi, P. P. McCann, and A. Sjoedsma. 1986. Uptake of a-difluoromethylornithine by Trypanosoma brucei brucei. Biochem. Pharmacol. 35:351-354.
9. Brun, R., and C. Kunz. 1989. In vitro drug sensitivity test for Trypanosoma brucei subgroup bloodstream trypomastigotes. Acta Trop. 46:361-368.
10. Cooper, K. D., J. B. Shukla, and O. M. Rennert. 1978. Polyamine compartimentalization in various human disease states. Clin. Chim. Acta 82:1-7.
11. Elias, S., B. Bercovich, C. Kahana, P. Coffino, M. Fischer, W. Hilt, D. H. Wolf, and A. Cicchanover. 1995. Degradation of ornithine decarboxylase by the mammalian and yeast 26S proteasome complexes requires all the components of the protease. Eur. J. Biochem. 229:276-283.
12. Hamm, B., A. Schindler, D. Mecke, and M. Duszenko. 1990. Differentiation of Trypanosoma brucei trypomastigotes from long slender to short stumpy-like forms in axcnic culture. Mol. Biochem. Parasitol. 40:13-22.
13. Iten, M., E. Matovu, R. Brun, and R. Kaminsky. 1995. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-α - difluoromethylornithine (DFMO). Trop. Med. Parasitol. 46:190-194.
14. Kaminsky, R., F. Chuma, and E. Zweygarth. 1989. Trypanosoma brucei brucei: expression of drug resistance in vitro. Exp. Parasitol. 69:281-289.
15. Lanham, S. M., and D. G. Godfrey. 1970. Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp. Parasitol. 28:521-534.
16. Mehlitz, D., U. Brinkmann, and L. Haller. 1981. Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part I. Review of literature and description of the study areas. Tropenmed. Parasitol. 32:129-133.
17. Metcalf, B. W., P. Bey, C. Danzin, M. J. Jung, P. Casara, and J. P. Vevert. 1978. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogues. J. Am. Chem. Soc. 100: 2551-2553.
18. Milord, F., L. Loko, L. Ethier, B. Mpia, and J. Pépin. 1993. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans. R. Soc. Trop. Med. Hyg. 87:473-477.
19. Murakami, Y., S. Matsufuji, Y. Miyazaki, and S. Hayash. 1992. Destabilization of ornithine decarboxylase by transfected antizyme gene expression in hepatoma tissue culture cells. J. Biol. Chem. 267:13138-13141.
20. Pegg, A. E., and P. P. McCann. 1982. Polyamine metabolism and function. Am. J. Cell. Physiol. 243:C212-C221.
21. Phillips, M. A., P. Coffino, and C. C. Wang. 1987. Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. J. Biol. Chem. 262:8721-8727.
22. Phillips, M. A., and C. C. Wang. 1987. A Trypanosoma brucei mutant resistant to α-difluoromethylornithine. Mol. Biol. Parasitol. 22:9-17.
23. Rogers, S., R. Wells, and M. Rechsteiner. 1986. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 234: 364-368.
24. Svensson, F., C. Ceriani, E. L. Wallström, I. Kockum, I. D. Algranati, O. Heby, and L. Persson. 1997. Cloning of a trypanosomatid gene coding for an ornithine decarboxylase that is metabolically unstable even though it lacks the C-terminal degradation domain. Proc. Natl. Acad. Sci. USA 94:397-402.
25. Tabor, C. W., and H. Tabor. 1984. Polyamines. Annu. Rev. Biochem. 53: 749-790.
26. Van Nieuwenhove, S., P. J. Schechter, J. Declercq, G. Bone, J. Burke, and A. Sjoerdsma. 1985. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-α-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans. R. Soc. Trop. Med. Hyg. 79:692-698.